{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:33:24Z","timestamp":1784608404742,"version":"3.55.0"},"publisher-location":"Cham","reference-count":97,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030573683","type":"print"},{"value":"9783030573690","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-57369-0_9","type":"book-chapter","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T09:26:59Z","timestamp":1608197219000},"page":"131-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Psychiatric Disorders and Cannabinoid Receptors"],"prefix":"10.1007","author":[{"given":"Neal","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Onaivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"9_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1037\/pha0000308","volume":"27","author":"A Acheson","year":"2019","unstructured":"Acheson A, Fantegrossi E (2019) Introduction to special issue: therapeutic and abuse-related effects of cannabis and cannabinoids. Exp Clin Psychoparmaco 27:299\u2013230","journal-title":"Exp Clin Psychoparmaco"},{"issue":"1","key":"9_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/03602532.2018.1428341","volume":"50","author":"M Alaverdashvili","year":"2018","unstructured":"Alaverdashvili M, Lapraire RB (2018) The future of type 1 cannabinoid receptor allosteric ligands. Drug Met Rev 50(1):14\u201325. https:\/\/doi.org\/10.1080\/03602532.2018.1428341","journal-title":"Drug Met Rev"},{"key":"9_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbb.2019.03.006","volume":"180","author":"AK Andrade","year":"2019","unstructured":"Andrade AK, Renda B, Murray JE (2019) Cannabinoids, interoception, and anxiety. Pharmacol Biochem Behav 180:60\u201373","journal-title":"Pharmacol Biochem Behav"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1017\/neu.2019.21","volume":"31","author":"S Arjmand","year":"2019","unstructured":"Arjmand S, Behzadi M, Kohlmeier KA, Mazhari S (2019) Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatrica 31:193\u2013201","journal-title":"Acta Neuropsychiatrica"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jnc.14098","volume":"142","author":"BS Basavarajappa","year":"2017","unstructured":"Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S (2017) Endocannabinoid system in neurodegenerative disorders. J Neurochem 142:624\u2013648","journal-title":"J Neurochem"},{"key":"9_CR6","doi-asserted-by":"publisher","unstructured":"Brigida AL, Schultz S, Cascone M, Antonuchi N, Siniscalco D. Endocannabinod signal Dysregulation in autism Spectrum disorders: a correlation link between inflammatory state and Neuro-immune alterations. Int J Mol Sci. 18(7). pii: E1425. doi: https:\/\/doi.org\/10.3390\/ijms18071425. 2017","DOI":"10.3390\/ijms18071425"},{"key":"9_CR7","doi-asserted-by":"publisher","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","volume":"287","author":"L Call\u00e9n","year":"2012","unstructured":"Call\u00e9n L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cort\u00e9s A, Mallol J et al (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 287:20851\u201320865","journal-title":"J Biol Chem"},{"key":"9_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrendo.2015.211","volume":"12","author":"PD Cani","year":"2016","unstructured":"Cani PD, Plovier H, Hul MV, Geurts L, Delzenne NM, Druart C et al (2016) Endocannabinoids- at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinology 12:133\u2013146","journal-title":"Nat Rev Endocrinology"},{"key":"9_CR9","volume-title":"Neurodevelopmental and behavioral alterations after conditional deletion of type 2 cannabinoid receptors in dopamine neurons","author":"A Canseco-Alba","year":"2018","unstructured":"Canseco-Alba A, Hammouda M, Schanz N, Liu QR, Onaivi ES (2018a) Neurodevelopmental and behavioral alterations after conditional deletion of type 2 cannabinoid receptors in dopamine neurons. Soc Neurosc Abst, San Diego"},{"key":"9_CR10","doi-asserted-by":"publisher","unstructured":"Canseco-Alba A, Schanz N, Ishiguro H, Liu QR, Onaivi ES. Behavioral Evaluation of Seeking and Preference of Alcohol in Mice Subjected to Stress. Bio Protoc. 8(20). pii: e3061. doi: https:\/\/doi.org\/10.21769\/BioProtoc.3061. 2018b","DOI":"10.21769\/BioProtoc.3061"},{"key":"9_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbr.2018.11.043","volume":"360","author":"A Canseco-Alba","year":"2019","unstructured":"Canseco-Alba A, Schanz N, Sanabria B, Zhao J, Lin Z, Liu QR et al (2019) Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons. Behav Brain Res 360:286\u2013297. https:\/\/doi.org\/10.1016\/j.bbr.2018.11.043","journal-title":"Behav Brain Res"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2012.09.020","volume":"76","author":"PE Castillo","year":"2012","unstructured":"Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76:70\u201381","journal-title":"Neuron"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","volume":"12","author":"B Chakrabarti","year":"2015","unstructured":"Chakrabarti B, Persico A, Battista N, Maccarrone M (2015) Endocannabinoid signaling in autism. Neurotherapeutics 12:837\u2013847","journal-title":"Neurotherapeutics"},{"issue":"Suppl 1","key":"9_CR14","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1073\/pnas.0906080106","volume":"107","author":"B Crespi","year":"2010","unstructured":"Crespi B, Stead P, Elliot M (2010) Evolution in health and medicine Sackler colloquium: comparative genomics of autism and schizophrenia. Proc Natl Acad Sci 107(Suppl 1):1736\u20131741. https:\/\/doi.org\/10.1073\/pnas.0906080106","journal-title":"Proc Natl Acad Sci"},{"key":"9_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuropharm.2017.01.031","volume":"122","author":"FT Crews","year":"2017","unstructured":"Crews FT, Lawrimore CJ, Walter TJ, Coleman LG Jr (2017) The role of neuroimmune signaling in alcoholism. Neuropharmacology 122:56\u201373","journal-title":"Neuropharmacology"},{"key":"9_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jpeds.2018.02.005","volume":"197","author":"TL Crume","year":"2018","unstructured":"Crume TL, Juhl AL, Brooks-Russel A, Hall KE, Wymore E, Borgelt LM (2018) Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: the association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. J Pediatr 197:90\u201396","journal-title":"J Pediatr"},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.schres.2017.01.022","volume":"188","author":"C D\u2019Addario","year":"2017","unstructured":"D\u2019Addario C, Micale V, Di Bartolomeo M, Stark T, Pucci M, Sulcova A et al (2017) A preliminary study of endocannabinoid system regulation in psychosis: distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophr Res 188:132\u2013140","journal-title":"Schizophr Res"},{"issue":"7","key":"9_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00406-018-0874-6","volume":"268","author":"V de Aleida","year":"2018","unstructured":"de Aleida V, Martins-de-Souza D (2018) Cannabinoids and glial cells: possible mechanism to understand schizophrenia. Eur Arch Psych Clin Neurosci 268(7):727\u2013737. https:\/\/doi.org\/10.1007\/s00406-018-0874-6","journal-title":"Eur Arch Psych Clin Neurosci"},{"key":"9_CR19","doi-asserted-by":"crossref","unstructured":"De Luca MA, Fattore L (2015) Cannabinoids and drug addiction. In: Fattore L (ed) Cannabinoids in neurologic and mental disease. Elsevier, pp 289\u2013314","DOI":"10.1016\/B978-0-12-417041-4.00012-6"},{"key":"9_CR20","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"37","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al (2017) Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in Dravet syndrome. N Engl J Med 37:2011\u20132020. https:\/\/doi.org\/10.1056\/NEJMoa1611618","journal-title":"N Engl J Med"},{"key":"9_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd.2018.115","volume":"17","author":"V Di Marzo","year":"2018","unstructured":"Di Marzo V (2018) New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov 17:623\u2013639","journal-title":"Nat Rev Drug Discov"},{"key":"9_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/can.2016.0001","volume":"1","author":"NV DiPatrizio","year":"2016","unstructured":"DiPatrizio NV (2016) Endocannabinoids in the gut. Cannabis Cannabinoid Res 1:1. https:\/\/doi.org\/10.1089\/can.2016.0001","journal-title":"Cannabis Cannabinoid Res"},{"key":"9_CR23","unstructured":"Ghose H. (2009) Cannabinoid controversy. http:\/\/www.the-scientist.com\/news\/display\/55969\/)"},{"key":"9_CR24","doi-asserted-by":"publisher","unstructured":"Guggenhuber S, Romo-Parra H, Bindila L, Leschik J, Lomazzo E, Remmers F et al (2015) Impaired 2-AG signaling in hippocampal neurons: aggravation of anxiety-like behavior and unaltered seizure susceptibility. Int J Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/ijn\/pyv091","DOI":"10.1093\/ijn\/pyv091"},{"issue":"4","key":"9_CR25","doi-asserted-by":"publisher","first-page":"e009986","DOI":"10.1136\/bmjopen-2015-009986","volume":"6","author":"JK Gunn","year":"2016","unstructured":"Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C et al (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BML Open 6(4):e009986. https:\/\/doi.org\/10.1136\/bmjopen-2015-009986","journal-title":"BML Open"},{"issue":"3","key":"9_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1017\/S1092852915000929","volume":"21","author":"DC Hesdorffer","year":"2016","unstructured":"Hesdorffer DC (2016) Comorbidity between neurological illness and psychiatric disorders. CNS Spectr 21(3):230\u2013238. https:\/\/doi.org\/10.1017\/S1092852915000929","journal-title":"CNS Spectr"},{"key":"9_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pharmthera.2011.09.002","volume":"133","author":"A Hill","year":"2012","unstructured":"Hill A, Williams CM, Whalley BJ, Stephens GJ (2012) Phytocannabinoids as novel therapeutic agents in CNS. Pharmacol Therapeutics 133:79\u201397","journal-title":"Pharmacol Therapeutics"},{"key":"9_CR28","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","volume":"167","author":"T Hua","year":"2016","unstructured":"Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y et al (2016) Crystal structure of human cannabinoid receptor 1. Cell 167:750\u2013762","journal-title":"Cell"},{"issue":"2","key":"9_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/sj.mp.4001376","volume":"9","author":"BL Hungund","year":"2004","unstructured":"Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB et al (2004) Upregulation of CB 1 receptors and agonist-stimulated [35 S] GTP\u03b3S binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 9(2):184","journal-title":"Mol Psychiatry"},{"key":"9_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcp.2018.07.009","volume":"151","author":"I Ibarra-Lecue","year":"2018","unstructured":"Ibarra-Lecue I, Pilar-Cuellar F, Muguruza C, Florensa-Zanuy E, Diaz A, Uriguen L et al (2018) The endocannabinoid system in mental disorders: evidence from human brain studies. Biochem Pharmacol 151:97\u2013107","journal-title":"Biochem Pharmacol"},{"key":"9_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fphar.2019.00350","volume":"10","author":"MS Ibsen","year":"2019","unstructured":"Ibsen MS, Finlay DB, Patel M, Javitch JA, Glass M, Grimsey NL (2019) Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence. Front Pharmacol 10:350. https:\/\/doi.org\/10.3389\/fphar.2019.00350","journal-title":"Front Pharmacol"},{"key":"9_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/syn.20714","volume":"64","author":"H Ishiguro","year":"2010","unstructured":"Ishiguro H, Carpio O, Horiuchi Y, Shu A, Higuchi S, Schanz N, Benno R et al (2010b) A nonsynonymous polymorphism in cannabinoid CB2 receptor gene is associated with eating disorders in humans and food intake is modified in mice by its ligands. Synapse 64:92\u201396","journal-title":"Synapse"},{"key":"9_CR33","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","volume":"67","author":"H Ishiguro","year":"2010","unstructured":"Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y et al (2010a) Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67:974\u2013982","journal-title":"Biol Psychiatry"},{"key":"9_CR34","doi-asserted-by":"publisher","unstructured":"Ishiguro H, Horiuchi Y, Tabata K, Liu QR, Arinami T, Onaivi ES (2018) Cannabinoid CB2 receptor gene and environmental interaction in the development of psychiatric disorders. Molecules 23. https:\/\/doi.org\/10.3390\/molecules23081836","DOI":"10.3390\/molecules23081836"},{"key":"9_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/sj.tpj.6500431","volume":"7","author":"H Ishiguro","year":"2007","unstructured":"Ishiguro H, Iwasaki S, Teasenfitz L, Higuchi S, Horiuchi Y, Saito T et al (2007) Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J 7:380\u2013385","journal-title":"Pharmacogenomics J"},{"key":"9_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-21737-2_1","volume":"1162","author":"N Josh","year":"2019","unstructured":"Josh N, Onaivi ES (2019) Endocannabinoid system components: overview and tissue distribution. Adv Exp Med Biol 1162:1\u201312","journal-title":"Adv Exp Med Biol"},{"key":"9_CR37","doi-asserted-by":"publisher","first-page":"eaat5236","DOI":"10.1126\/science.aat5236","volume":"361","author":"MM Kaelberer","year":"2018","unstructured":"Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X (2018) A gut-brain neural circuit for nutrient sensory transduction. Science 361:eaat5236. https:\/\/doi.org\/10.1126\/science.aat5236","journal-title":"Science"},{"key":"9_CR38","doi-asserted-by":"publisher","first-page":"108717","DOI":"10.1016\/j.biopha.2019.108717","volume":"112","author":"F Khakpai","year":"2019","unstructured":"Khakpai F, Ebrahimi-Ghiri M, Alijanpour S, Zarrindast MR (2019) Ketamine-induced antidepressant like effects in mice: a possible involvement of cannabinoid system. Biomed Pharmacother 112:108717","journal-title":"Biomed Pharmacother"},{"key":"9_CR39","doi-asserted-by":"publisher","unstructured":"Kill KP (2019) Medical use of cannabis in 2019. JAMA. https:\/\/doi.org\/10.1001\/Jama.2019.11868","DOI":"10.1001\/Jama.2019.11868"},{"issue":"8","key":"9_CR40","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","volume":"114","author":"D Koethe","year":"2007","unstructured":"Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM et al (2007) Expression of CB 1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114(8):1055","journal-title":"J Neural Transm"},{"key":"9_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1515\/jbcpp-2015-0058","volume":"27","author":"N Korem","year":"2016","unstructured":"Korem N, Zer-Aviv TM, Ganon-Elazar E, Abush H, Akirav I (2016) Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol 27:193\u2013202","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"9_CR42","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/ejp.1377","volume":"23","author":"MO Krebs","year":"2019","unstructured":"Krebs MO, Kebir O, Jay TM (2019) Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. Eur J Pain 23:1225\u20131233","journal-title":"Eur J Pain"},{"key":"9_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2016.10.005","volume":"32","author":"RB Laprairie","year":"2017","unstructured":"Laprairie RB, Bagher AM, Denovan-Wright EM (2017a) Cannabinoid receptor ligand bias: implications in the central nervous system. Curr Opin Pharmacol 32:32\u201343","journal-title":"Curr Opin Pharmacol"},{"key":"9_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2019.03.033","volume":"151","author":"RB Laprairie","year":"2019","unstructured":"Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM et al (2019) Positive allosteric modulation of type 1 cannabinoid receptor reduces the signs and symptoms of Huntington\u2019s disease in the R6\/2 mouse model. Neuropharmacology 151:1\u201312","journal-title":"Neuropharmacology"},{"key":"9_CR45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","volume":"8","author":"RB Laprairie","year":"2017","unstructured":"Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG et al (2017b) Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chem Neurosci 8:1188\u20131203","journal-title":"ACS Chem Neurosci"},{"key":"9_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","volume":"176","author":"X Li","year":"2019","unstructured":"Li X, Hua T, Vemuri K, Ho JH, Wu Y, Wu L et al (2019) Crystal structure of the human cannabinoid receptor CB2. Cell 176:459\u2013467","journal-title":"Cell"},{"key":"9_CR47","first-page":"451","volume":"65","author":"X-H Lin","year":"2013","unstructured":"Lin X-H, Wang Y-Q, Wang H-C, Ren X-Q, Li Y-Y (2013) Role of endogenous cannabinoid system in the gut. Acta Physiologica Sinica 65:451\u2013460","journal-title":"Acta Physiologica Sinica"},{"key":"9_CR48","doi-asserted-by":"publisher","first-page":"17410","DOI":"10.1038\/s41598-017-17796-y","volume":"7","author":"QR Liu","year":"2017","unstructured":"Liu QR, Canseco-Alba A, Zhang HY, Taglaiferro P, Chung M, Dennis E et al (2017) Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference. Sci Rep 7:17410","journal-title":"Sci Rep"},{"key":"9_CR49","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40263-015-0270-y","volume":"29","author":"CS Liu","year":"2015","unstructured":"Liu CS, Chau SA, Ruthirakuhan M, Lanct\u00f4t KL, Herrmann N (2015) Cannabinoids for the treatment of agitation and aggression in Alzheimer\u2019s disease. CNS Drugs 29:615\u2013623","journal-title":"CNS Drugs"},{"key":"9_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","volume":"15","author":"A Lopez","year":"2018","unstructured":"Lopez A, Aparicio N, Pazos MR, Grande MT, Barreda-Manso MA, Benito-Cuesta I et al (2018) Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer\u2019s disease. Neuroinflammation 15:158","journal-title":"Neuroinflammation"},{"key":"9_CR51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","volume":"269","author":"DJE Lowe","year":"2019","unstructured":"Lowe DJE, Sasiadek JD, Coles AS, George TP (2019) Cannabis and mental illness: a review. Europ Arch Psychiat and Clin Neurosci 269:107\u2013120","journal-title":"Europ Arch Psychiat and Clin Neurosci"},{"key":"9_CR52","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/npp.2010.19","volume":"35","author":"M Maccarrone","year":"2010","unstructured":"Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A et al (2010) Abnormal mGlu 5 receptor\/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 35:1500\u20131509","journal-title":"Neuropsychopharmacology"},{"key":"9_CR53","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1089\/neu.2018.6063","volume":"36","author":"L Magid","year":"2019","unstructured":"Magid L, Heymann S, Elgali M, Avram L, Cohen Y, Liraz-Zaltsman S et al (2019) Role of CB2 receptor in recovery of mice after traumatic brain injury. J Neurotrauma 36:1836\u20131846","journal-title":"J Neurotrauma"},{"key":"9_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/S1355617707070889","volume":"13","author":"L Malloy-Diniz","year":"2007","unstructured":"Malloy-Diniz L, Fuentes D, Leite WB, Correa H, Bechara A (2007) Impulsive behavior in adults with attention deficit\/hyperactivity disorder: characterization of attentional, motor and cognitive impulsiveness. J Int Neuropsychol Soc 13:693\u2013698","journal-title":"J Int Neuropsychol Soc"},{"key":"9_CR55","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1038\/s41598-017-15154-6","volume":"7","author":"P Mehrpouya-Bahrami","year":"2017","unstructured":"Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, Tang C, Murphy EA, Enos RT et al (2017) Blockade of CB1 cannabinoid receptors alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep 7:15645. https:\/\/doi.org\/10.1038\/s41598-017-15154-6","journal-title":"Sci Rep"},{"key":"9_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neuropharm.2017.03.033","volume":"124","author":"M Melis","year":"2017","unstructured":"Melis M, Frau R, Kalivas PW, Spencer S, Chioma V, Zamberletti E et al (2017) New visitas on cannabis use disorder. Neuropharmacology 124:62\u201372","journal-title":"Neuropharmacology"},{"key":"9_CR57","doi-asserted-by":"publisher","DOI":"10.17226\/24625","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, Washington, DC. https:\/\/doi.org\/10.17226\/24625"},{"key":"9_CR58","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fonc.2017.00208","volume":"7","author":"W Ngwa","year":"2017","unstructured":"Ngwa W, Kumar R, Moreau M, Dabney R, Herman A (2017) Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids. Front Oncol 7:208. https:\/\/doi.org\/10.3389\/fonc.2017.00208","journal-title":"Front Oncol"},{"key":"9_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29:1\u20138","journal-title":"Curr Opin Neurobiol"},{"key":"9_CR60","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1196\/annals.1432.056","volume":"1139","author":"ES Onaivi","year":"2008","unstructured":"Onaivi ES (2008) An endocannabinoid hypothesis of drug reward and drug addiction. Ann N Y Acad Sci 1139:412\u2013421","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"9_CR61","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2217\/pgs.10.91","volume":"11","author":"ES Onaivi","year":"2010","unstructured":"Onaivi ES (2010) Endocannabinoid system, pharmacogenomics and response to therapy. Pharmacogenomics 11(7):907\u2013910","journal-title":"Pharmacogenomics"},{"key":"9_CR62","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/157015911795017047","volume":"9","author":"ES Onaivi","year":"2011","unstructured":"Onaivi ES, Benno R, Halpern T, Mehanovic M, Schanz N, Sanders C et al (2011) Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol 9:209\u2013214. https:\/\/doi.org\/10.2174\/157015911795017047","journal-title":"Curr Neuropharmacol"},{"key":"9_CR63","unstructured":"Onaivi ES, Canseco-Alba B. D. Sanabria BD, Zhang HY, Eita M, Rohani T et al. Identification of cannabinoid CB2 receptor neuro-immune crosstalk following conditional deletion of type 2 cannabinoid receptors in microglia and dopamine neurons. Soc Neurosc Abst. San Diego. 2018"},{"key":"9_CR64","first-page":"1002","volume":"252","author":"ES Onaivi","year":"1990","unstructured":"Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. The J Pharmaco Expl Ther 252:1002\u20131009","journal-title":"The J Pharmaco Expl Ther"},{"issue":"2","key":"9_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001640","volume":"3","author":"ES Onaivi","year":"2008","unstructured":"Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L et al (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 3(2):e1640","journal-title":"PLoS One"},{"key":"9_CR66","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1196\/annals.1369.052","volume":"1074","author":"ES Onaivi","year":"2006","unstructured":"Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA (2006b) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514\u2013536","journal-title":"Ann N Y Acad Sci"},{"key":"9_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/0269881111400652","volume":"26","author":"ES Onaivi","year":"2012","unstructured":"Onaivi ES, Ishiguro H, Gu S, Liu QR (2012) CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 26:92\u2013103","journal-title":"J Psychopharmacol"},{"key":"9_CR68","doi-asserted-by":"crossref","unstructured":"Onaivi ES, Ishiguro H, Liu QR (2015) Future perspectives: cannabinoid CB2 receptor ligands and their therapeutic potential in mental diseases. In: Fattore L (ed) Cannabinoids in neurologic and mental disease. Elsevier Inc, pp 425\u2013444","DOI":"10.1016\/B978-0-12-417041-4.00018-7"},{"key":"9_CR69","doi-asserted-by":"publisher","unstructured":"Onaivi ES, Ishiguro H, Sgro S, Leonard CM (2013) Cannabinoid receptor gene variations in drug addiction and neuropsychiatric disorders. J Drug Alcohol Res. https:\/\/doi.org\/10.4303\/jdar\/235714","DOI":"10.4303\/jdar\/235714"},{"key":"9_CR70","volume-title":"Eds. Endocannabinoids: the brain and body\u2019s marijuana and beyond","author":"ES Onaivi","year":"2006","unstructured":"Onaivi ES, Sugiura T, DiMarzo V (2006a) Eds. Endocannabinoids: the brain and body\u2019s marijuana and beyond. CRC Press, Taylor and Francis Group, Boca Raton"},{"key":"9_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11920-019-1026-z","volume":"21","author":"EP Papagianni","year":"2019","unstructured":"Papagianni EP, Stevenson CW (2019) Cannabidiol regulation of fear and anxiety: an update. Curr Psychiatric Reports 21:38. https:\/\/doi.org\/10.1007\/s11920-019-1026-z","journal-title":"Curr Psychiatric Reports"},{"key":"9_CR72","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4172\/2329-6488.1000259","volume":"5","author":"T Parira","year":"2017","unstructured":"Parira T, Laverde A, Agudelo M (2017) Epigenetic interactions between alcohol and cannabinergic effects: focus on histone modification and DNA methylation. J Alcohol Depend 5:259. https:\/\/doi.org\/10.4172\/2329-6488.1000259","journal-title":"J Alcohol Depend"},{"key":"9_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16:1\u201333","journal-title":"J Nanobiotechnol"},{"key":"9_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.lfs.2018.09.058","volume":"213","author":"E Poleszak","year":"2018","unstructured":"Poleszak E, Wosko S, Salwinska K, Szopa A, Wrobel A, Serefko A (2018) Cannabinoids in depressive disorders. Life Sci 213:18\u201324","journal-title":"Life Sci"},{"key":"9_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lfs.2019.03.053","volume":"224","author":"M Premoli","year":"2019","unstructured":"Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD (2019) Cannabidiol: recent advances and new insights for neuropsychiatric disorders. Life Sci 224:120\u2013127","journal-title":"Life Sci"},{"key":"9_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/dta.1529","volume":"6","author":"PJ Robson","year":"2014","unstructured":"Robson PJ (2014) Therapeutic potential of cannabinoid medicines. Drug Test Analysis 6:24\u201330","journal-title":"Drug Test Analysis"},{"key":"9_CR77","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neuropharm.2013.07.013","volume":"75","author":"M Rodriguez-Arias","year":"2013","unstructured":"Rodriguez-Arias M, Navarrete F, Daza-Losada M, Navarro D, Aguilar MA, Berbel P et al (2013) CB1 cannabinoid receptor-mediated aggressive behavior. Neuropharmacology 75:172\u2013180","journal-title":"Neuropharmacology"},{"key":"9_CR78","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jama.2018.11914","volume":"320","author":"R Rubin","year":"2018","unstructured":"Rubin R (2018) The path to the first FDA-approved cannabis-derived treatment and what comes next. JAMA 320:1227\u20131229. https:\/\/doi.org\/10.1001\/jama.2018.11914","journal-title":"JAMA"},{"key":"9_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnint.2018.00051","volume":"12","author":"EB Russo","year":"2018","unstructured":"Russo EB (2018) Cannabis therapeutics and the future of neurology. Front Integr Neurosci 12:51. https:\/\/doi.org\/10.3389\/fnint.2018.00051","journal-title":"Front Integr Neurosci"},{"issue":"9","key":"9_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138986","volume":"10","author":"AC Schm\u00f6le","year":"2015","unstructured":"Schm\u00f6le AC, Lundt R, Gennequin B, Schrage H, Beins E, Kr\u00e4mer A et al (2015) Expression analysis of CB2-GFP BAC transgenic mice. PLoS One 10(9):e0138986","journal-title":"PLoS One"},{"key":"9_CR81","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/IJN.S157958","volume":"13","author":"P Singh","year":"2018","unstructured":"Singh P, Pandit S, Garnaes J, Tunic S, Mokkapati VR, Sultan A et al (2018) Green synthesis of gold and silver nanoparticles from cannabis sativa (industrial hemp) and their capacity for biofilm inhibition. Int J Nanomedicine 13:3571\u20133591","journal-title":"Int J Nanomedicine"},{"key":"9_CR82","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41401-018-0081-z","volume":"40","author":"ME Sloan","year":"2018","unstructured":"Sloan ME, Grant CW, Gowin JL, Ramchandani VJ, Le Foll B (2018) Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. Act Pharmacologica Sinca 40:342\u2013350","journal-title":"Act Pharmacologica Sinca"},{"issue":"11","key":"9_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187926","volume":"12","author":"DR Smith","year":"2017","unstructured":"Smith DR, Stanley CM, Foss T, Boles RG, McKernan K (2017) Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans. PLoS One 12(11):e0187926","journal-title":"PLoS One"},{"key":"9_CR84","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1039\/C7CS00877E","volume":"47","author":"CD Spicer","year":"2018","unstructured":"Spicer CD, Jumeaux C, Gupta B, Stevens MM (2018) Peptide and protein nanoparticle conjugates versatile platforms for biomedical applications. Chem Soc Rev 47:3574\u20133620","journal-title":"Chem Soc Rev"},{"key":"9_CR85","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.neuron.2016.03.034","volume":"90","author":"AV Stempel","year":"2016","unstructured":"Stempel AV, Zhang HY, Ozdogan T, Pannasch U, Theis AK (2016) Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron 90:795\u2013809","journal-title":"Neuron"},{"key":"9_CR86","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bph.14440","volume":"176","author":"M Tham","year":"2019","unstructured":"Tham M, Yilmaz O, Alaverdasvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB (2019) Allosteric and orthesteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type cannabinoid receptors. Br J Pharmacol 176:1455\u20131469","journal-title":"Br J Pharmacol"},{"key":"9_CR87","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thielle","year":"2018","unstructured":"Thielle EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C et al (2018) Cannabidiol in patients with seizures associated with Lennos-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 391:1085\u20131096. https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3","journal-title":"Lancet"},{"key":"9_CR88","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.psychres.2018.12.170","volume":"272","author":"NE Turner","year":"2019","unstructured":"Turner NE, McDonald AJ, Lalomiteanu AR, Mann RE, McCready J, Millstone D et al (2019) Moderate to severe gambling problems and traumatic brain injury: a population-based study. Psychiatry Res 272:692\u2013697. https:\/\/doi.org\/10.1016\/j.psychres.2018.12.170","journal-title":"Psychiatry Res"},{"issue":"1","key":"9_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11126-018-9617-0","volume":"90","author":"MG Vaughn","year":"2019","unstructured":"Vaughn MG, Sala-Wright CP, John R, Holzer KJ, Qian Z, Veeh C (2019) Traumatic brain injury and psychiatric co-morbidity in the United States. Psychiatry Q 90(1):151\u2013158. https:\/\/doi.org\/10.1007\/s11126-018-9617-0","journal-title":"Psychiatry Q"},{"key":"9_CR90","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41401-018-0051-5","volume":"40","author":"A Yin","year":"2018","unstructured":"Yin A, Wang F, Zhang X (2018) Integrating endocannabinoid signaling in the regulation of anxiety and depression. Act Pharmacologica Sinca. 40:336\u2013341","journal-title":"Act Pharmacologica Sinca."},{"key":"9_CR91","doi-asserted-by":"publisher","unstructured":"Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: insights from animal models. Int J Mol Sci, 18(9). Pii: E1916. Doi: https:\/\/doi.org\/10.3390\/ijms18091916. 2017","DOI":"10.3390\/ijms18091916"},{"key":"9_CR92","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1523\/JNEUROSCI.0795-10.2010","volume":"30","author":"L Zhang","year":"2010","unstructured":"Zhang L, Alger BE (2010) Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 30:5724\u20135729","journal-title":"J Neurosci"},{"key":"9_CR93","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/sj.mp.4001560","volume":"9","author":"PW Zhang","year":"2004","unstructured":"Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al (2004) Human cannabinoid receptor 1:5\u2032 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9:916\u2013931","journal-title":"Mol Psychiatry"},{"key":"9_CR94","first-page":"435","volume":"72","author":"D Zhou","year":"2017","unstructured":"Zhou D, Li Y, Tian T, Quan W, Wang L, Shao Q et al (2017) Role of the endocannabinoid system in the formation and development of depression. Pharmazie 72:435\u2013439","journal-title":"Pharmazie"},{"key":"9_CR95","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2019","unstructured":"Zou S, Kumar U (2019) Cannabinoid receptors and endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19:833. https:\/\/doi.org\/10.3390\/ijms19030833","journal-title":"Int J Mol Sci"},{"key":"9_CR96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijdevneu.2019.03.002","volume":"76","author":"M Zou","year":"2019","unstructured":"Zou M, Li D, Wu L, Sun C (2019) Role of the endocannabinoid system in neurological disorders. Int J Dev Neurosci 76:95\u2013102","journal-title":"Int J Dev Neurosci"},{"key":"9_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11481-015-9586-0","volume":"10","author":"EE Zumbrun","year":"2015","unstructured":"Zumbrun EE, Sido JM, Nagarkatti PS, Nagagarkatti PS (2015) Epigenetic regulation of immunological alterations following prenatal exposure to marijuana cannabinoids and its long-term consequences in offspring. J Neuroimmune Pharmacol 10:245\u2013254","journal-title":"J Neuroimmune Pharmacol"}],"container-title":["Advances in Experimental Medicine and Biology","Cannabinoids and Neuropsychiatric Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-57369-0_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:57:11Z","timestamp":1697378231000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-57369-0_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"ISBN":["9783030573683","9783030573690"],"references-count":97,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-57369-0_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"18 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}